Brought to you by 
Lynx Therapeutics licenses restenosis drug to Schwarz Pharma
28 Dec 1999
Executive Summary
Lynx Therapeutics has licensed European and North American rights to its coronary artery restenosis agent, LR-3280 to Schwarz Pharma in exchange for total payments of $20mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lynx Therapeutics licenses restenosis drug to Schwarz Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice